• No results found

Cover Page The handle http://hdl.handle.net/1887/3176524 holds various files of this Leiden University dissertation. Author: Buikhuisen, W.A. Title: Angiogenesis in mesothelioma Issue date: 2021-06-02

N/A
N/A
Protected

Academic year: 2021

Share "Cover Page The handle http://hdl.handle.net/1887/3176524 holds various files of this Leiden University dissertation. Author: Buikhuisen, W.A. Title: Angiogenesis in mesothelioma Issue date: 2021-06-02"

Copied!
6
0
0

Bezig met laden.... (Bekijk nu de volledige tekst)

Hele tekst

(1)

Cover Page

The handle http://hdl.handle.net/1887/3176524 holds various files of this Leiden

University dissertation.

Author: Buikhuisen, W.A.

Title: Angiogenesis in mesothelioma

Issue date: 2021-06-02

(2)

Angiogenesis in Mesothelioma

(3)

Cover ProefschriftMaken | De Bilt

Cover image Starline / Freepik

Layout Renate Siebes | Proefschrift.nu

Printed by ProefschriftMaken | De Bilt

ISBN 978-94-6423-262-2

© Wieneke Buikhuisen 2021

All rights reserved. No part of this thesis may be reproduced, stored or transmitted in any form or by any means, without prior permission of the author, or, when applicable, of the publishers of the scientific papers.

(4)

Angiogenesis in Mesothelioma

Proefschrift

ter verkrijging van

de graad van doctor aan de Universiteit Leiden, op gezag van rector magnificus prof.dr.ir. H. Bijl, volgens besluit van het college voor promoties

te verdedigen op woensdag 2 juni 2021 klokke 13.45 uur

door

Wieneke Alexandra Buikhuisen

geboren te Leiden

(5)

Promotor

Prof.dr. P. Baas

Copromotor

Dr. J.A. Burgers (Antoni van Leeuwenhoek)

Leden promotiecommissie

Prof.dr. P.S. Hiemstra Prof.dr. C.A.M. Marijnen

Prof.dr. J.P. Van Meerbeeck (Universitair Ziekenhuis Antwerpen, België) Prof. S. Popat (Royal Marsden Fulham Road, London, Verenigd Koninkrijk)

(6)

Chapter 1 General introduction and outline of the thesis 7 Chapter 2 Second-line therapy in malignant pleural mesothelioma:

a systematic review

25 Chapter 3 Thalidomide versus active supportive care for maintenance

in patients with malignant mesothelioma after first-line chemotherapy (NVALT 5): an open label, multicenter, randomised phase 3 study

59

Chapter 4 A randomised phase 2 study adding axitinib to pemetrexed-cisplatin in patients with malignant pleural mesothelioma: a single center trial combining clinical and translational outcomes

81

Chapter 5 Optimisation of response classification criteria for patients with malignant pleural mesothelioma, a validation study

107 Chapter 6 Antiangiogenic therapies for mesothelioma. What is the role

in mesothelioma treatment?

113

Chapter 7 Discussion and future perspectives 127

Appendices Nederlandse samenvatting List of publications Dankwoord Curriculum vitae 141 149 157 163

Table of contents

Referenties

GERELATEERDE DOCUMENTEN

ABS , PL -kùk plural plain absolutive marker for kùk L -plural nouns, and their plural formative for dative, locative and possessive case (IV.1.3.1) -n SG singular marker

After a short time with these men it became very clear that the Majang language had a surprise in store for me that I did not expect to find in an African language – a

It contains information about the location of the different language areas of Majang in relation to the areas of neighboring languages, the main roads in the area, the

Some morphemes of Majang are inherently toneless and copy the tone of the preceding syllable. In the surface representation used for most examples, these morphemes are shown with

The verb appears therefore in the (apparently un- marked) disjoint form, although the whole VP is conjoint (section IV.3.4.2). The conjoint-disjoint distinction is quite useful for

Not many generalizations about the case marking of unmarked singular nouns are possible. The ergative has low tones on short vowels and HL se- quences on long

In addition, an uncontrolled, open-label, multicenter study conducted in China found that a regimen of single 3-g doses of fosfomycin tromethamine administered at two-day

A randomised phase 3 trial comparing atezolizumab plus bevacizumab and standard chemotherapy (carboplatin and pemetrexed) versus bevacizumab and standard chemotherapy as